2019 Hedge Fund

Acquisition International - Hedge Fund Awards 2019 7 Best Long/Short Biotech Fund (1 Year): Boxer Capital LLC of the Tavistock Group & Best Biotech Investment Firm 2019 an inhibitor with antiandrogen activity. In May of 2009, Cougar was acquired by Johnson and Johnson for $1 billion USD • Mirati Therapeutics (MRTX): MRTX is a clinical-stage oncology company developing targeted therapeutics to address the genetic, and immunological promoters of cancer Most of Boxer Capital’s investments begin from one of several proven investment theses, each involving substantial due diligence on fundamentals of the prospective company, paired with “big picture” thinking of the industry and sub-sectors. Through this disciplined methodology, the firm’s research and investment team identify opportunities to translate the inefficiencies of the biotechnology market into risk-adjusted returns over the short, medium, and long-term. Alongside their concentrated long portfolio exists an overall hedge of selective company and index shorts to balance their sector exposure in the markets. This investment approach has enabled Boxer Capital to remain a key player within the biotechnology investment space, giving it the ability to invest in research that will lead to some of the greatest developments in the medical markets in 2019 and beyond. Partnering with the brightest minds in science and medicine, Boxer Capital aims to help bring what was once only imaginable to reality. Every member of the Boxer Capital team takes pride in being at the forefront of improving outcomes for patients. Focusing most of their investment efforts on innovative discoveries that hold potential to bring life-saving options to patients, the firm has an underlying passion and expertise for investing in oncology. One of the current key challenges that exist within the biotechnology investment market is the continued drug pricing rhetoric and overhang from the political environment on desiring pricing change within the industry. Boxer Capital works to overcome these macro challenges of investing in the sector with a concentrated portfolio of long positions, focused mostly on companies developing drugs that will exponentially improve the current standard of care for patients; these must be “game changing” with a strong likelihood of success. Therefore, any major political or pricing shifts within the industry that may take form remain secondary in importance to the necessity for medical advancements to improve the daily lives of patients suffering from these illnesses. The firm’s key investor, Tavistock Group, is an international private investment organization founded by Joe Lewis over 40 years ago. Tavistock Group is built on a core philosophy to strive for excellence in everything it undertakes. Entrepreneurial and progressing, Tavistock Group values long-term relationships and identifies investment opportunities around the world that can benefit from capital, experience, flexibility, and a broad base of resources. Boxer Capital’s international infrastructure and scale, coupled with its deep experience in biotechnology drug development and investing, positions them as one the premier life science investment firms in the industry. The firm’s expert team includes scientists and clinicians who have been on the forefront of research and discovery across multiple therapeutic indications; such as cardiovascular health, oncology, and neurological disease, among others. Several of the firm’s partners continue to practice medicine and have had the privilege of leading clinical development for multiple drugs that are treating patients today. This unique combination of medical and investing expertise has led to a 13-year proven track record. Seeking to expand its marked success, Boxer Capital is working towards many exciting developments in the coming year. With strong returns since inception, Boxer Capital has expanded its team, adding several new members to its research department to help drive growth in 2019 and beyond, ensuring a bright future for both itself and Tavistock Group. “Boxer Capital’s international infrastructure and scale, coupled with its deep experience in biotechnology drug development and investing, positions them as one the premier life science investment firms in the industry.” “Through disciplined methodology, the firm’s research and investment team identify opportunities to translate the inefficiencies of the biotechnology market into risk- adjusted returns over the short, medium, and long-term.” Aaron Davis, Chief Executive Officer, Boxer Capital, LLC